Cargando…
Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidel...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397434/ https://www.ncbi.nlm.nih.gov/pubmed/30886730 http://dx.doi.org/10.1136/rmdopen-2018-000784 |
_version_ | 1783399414552854528 |
---|---|
author | Meyer, Alain Scirè, Carlo Alberto Talarico, Rosaria Alexander, Tobias Amoura, Zahir Avcin, Tadej Barsotti, Simone Beretta, Lorenzo Blagojevic, Jelena Burmester, Gerd Cavazzana, Ilaria Cherrin, Patrick Damian, Laura Doria, Andrea Fonseca, João Eurico Furini, Federica Galetti, Ilaria Houssiau, Frederic Krieg, Thomas Larosa, Maddalena Launay, David Campanilho-Marques, Raquel Martin, Thierry Matucci-Cerinic, Marco Moinzadeh, Pia Montecucco, Carlomaurizio Moraes-Fontes, Maria Francisca Mouthon, Luc Neri, Rossella Paolino, Sabrina Piette, Yves Rednic, Simona Tamirou, Farah Tincani, Angela Toplak, Natasa Bombardieri, Stefano Hachulla, Eric Mueller-Ladner, Ulf Schneider, Matthias Smith, Vanessa Vieira, Ana Cutolo, Maurizio Mosca, Marta Cavagna, Lorenzo |
author_facet | Meyer, Alain Scirè, Carlo Alberto Talarico, Rosaria Alexander, Tobias Amoura, Zahir Avcin, Tadej Barsotti, Simone Beretta, Lorenzo Blagojevic, Jelena Burmester, Gerd Cavazzana, Ilaria Cherrin, Patrick Damian, Laura Doria, Andrea Fonseca, João Eurico Furini, Federica Galetti, Ilaria Houssiau, Frederic Krieg, Thomas Larosa, Maddalena Launay, David Campanilho-Marques, Raquel Martin, Thierry Matucci-Cerinic, Marco Moinzadeh, Pia Montecucco, Carlomaurizio Moraes-Fontes, Maria Francisca Mouthon, Luc Neri, Rossella Paolino, Sabrina Piette, Yves Rednic, Simona Tamirou, Farah Tincani, Angela Toplak, Natasa Bombardieri, Stefano Hachulla, Eric Mueller-Ladner, Ulf Schneider, Matthias Smith, Vanessa Vieira, Ana Cutolo, Maurizio Mosca, Marta Cavagna, Lorenzo |
author_sort | Meyer, Alain |
collection | PubMed |
description | Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidelines (CPGs) have been proposed for IIMs, but they are sparse and heterogeneous. This work aimed at identifying: i) current available CPGs for IIMs, ii) patients ’ and clinicians’ unmet needs not covered by CPGs. It has been performed in the framework of the European Reference Network on rare and complex connective tissue and musculoskeletal diseases (ReCONNET), a network of centre of expertise and patients funded by the European Union’s Health Programme. Fourteen original CPGs were identified, notably recommending that: i) extra-muscular involvements should be assessed; ii) corticosteroids and methotrexate or azathioprine are first-line therapies of IIMs. ii) IVIG is a treatment of resistant-DM that may be also used in other resistant-IIMs; iii) physical therapy and sun protection (in DM patients) are part of the treatment; v) tumour screening for patients with DM include imaging of chest, abdomen, pelvis and breast (in woman) along with colonoscopy (in patients over 50 years); vi) disease activity and damages should be monitor using standardised and validated tools. Yet, only half of these CPGs were evidence-based. Crucial unmet needs were identified both by patients and clinicians. In particular, there was a lack of large multidisciplinary working group and of patients ’ preferences. The following fields were not or inappropriately targeted: diagnosis; management of extra-muscular involvements other than skin; co-morbidities and severe manifestations. |
format | Online Article Text |
id | pubmed-6397434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-63974342019-03-18 Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines Meyer, Alain Scirè, Carlo Alberto Talarico, Rosaria Alexander, Tobias Amoura, Zahir Avcin, Tadej Barsotti, Simone Beretta, Lorenzo Blagojevic, Jelena Burmester, Gerd Cavazzana, Ilaria Cherrin, Patrick Damian, Laura Doria, Andrea Fonseca, João Eurico Furini, Federica Galetti, Ilaria Houssiau, Frederic Krieg, Thomas Larosa, Maddalena Launay, David Campanilho-Marques, Raquel Martin, Thierry Matucci-Cerinic, Marco Moinzadeh, Pia Montecucco, Carlomaurizio Moraes-Fontes, Maria Francisca Mouthon, Luc Neri, Rossella Paolino, Sabrina Piette, Yves Rednic, Simona Tamirou, Farah Tincani, Angela Toplak, Natasa Bombardieri, Stefano Hachulla, Eric Mueller-Ladner, Ulf Schneider, Matthias Smith, Vanessa Vieira, Ana Cutolo, Maurizio Mosca, Marta Cavagna, Lorenzo RMD Open Connective Tissue Diseases Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidelines (CPGs) have been proposed for IIMs, but they are sparse and heterogeneous. This work aimed at identifying: i) current available CPGs for IIMs, ii) patients ’ and clinicians’ unmet needs not covered by CPGs. It has been performed in the framework of the European Reference Network on rare and complex connective tissue and musculoskeletal diseases (ReCONNET), a network of centre of expertise and patients funded by the European Union’s Health Programme. Fourteen original CPGs were identified, notably recommending that: i) extra-muscular involvements should be assessed; ii) corticosteroids and methotrexate or azathioprine are first-line therapies of IIMs. ii) IVIG is a treatment of resistant-DM that may be also used in other resistant-IIMs; iii) physical therapy and sun protection (in DM patients) are part of the treatment; v) tumour screening for patients with DM include imaging of chest, abdomen, pelvis and breast (in woman) along with colonoscopy (in patients over 50 years); vi) disease activity and damages should be monitor using standardised and validated tools. Yet, only half of these CPGs were evidence-based. Crucial unmet needs were identified both by patients and clinicians. In particular, there was a lack of large multidisciplinary working group and of patients ’ preferences. The following fields were not or inappropriately targeted: diagnosis; management of extra-muscular involvements other than skin; co-morbidities and severe manifestations. BMJ Publishing Group 2019-02-26 /pmc/articles/PMC6397434/ /pubmed/30886730 http://dx.doi.org/10.1136/rmdopen-2018-000784 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Connective Tissue Diseases Meyer, Alain Scirè, Carlo Alberto Talarico, Rosaria Alexander, Tobias Amoura, Zahir Avcin, Tadej Barsotti, Simone Beretta, Lorenzo Blagojevic, Jelena Burmester, Gerd Cavazzana, Ilaria Cherrin, Patrick Damian, Laura Doria, Andrea Fonseca, João Eurico Furini, Federica Galetti, Ilaria Houssiau, Frederic Krieg, Thomas Larosa, Maddalena Launay, David Campanilho-Marques, Raquel Martin, Thierry Matucci-Cerinic, Marco Moinzadeh, Pia Montecucco, Carlomaurizio Moraes-Fontes, Maria Francisca Mouthon, Luc Neri, Rossella Paolino, Sabrina Piette, Yves Rednic, Simona Tamirou, Farah Tincani, Angela Toplak, Natasa Bombardieri, Stefano Hachulla, Eric Mueller-Ladner, Ulf Schneider, Matthias Smith, Vanessa Vieira, Ana Cutolo, Maurizio Mosca, Marta Cavagna, Lorenzo Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines |
title | Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines |
title_full | Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines |
title_fullStr | Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines |
title_full_unstemmed | Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines |
title_short | Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines |
title_sort | idiopathic inflammatory myopathies: state of the art on clinical practice guidelines |
topic | Connective Tissue Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397434/ https://www.ncbi.nlm.nih.gov/pubmed/30886730 http://dx.doi.org/10.1136/rmdopen-2018-000784 |
work_keys_str_mv | AT meyeralain idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT scirecarloalberto idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT talaricorosaria idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT alexandertobias idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT amourazahir idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT avcintadej idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT barsottisimone idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT berettalorenzo idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT blagojevicjelena idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT burmestergerd idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT cavazzanailaria idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT cherrinpatrick idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT damianlaura idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT doriaandrea idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT fonsecajoaoeurico idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT furinifederica idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT galettiilaria idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT houssiaufrederic idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT kriegthomas idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT larosamaddalena idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT launaydavid idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT campanilhomarquesraquel idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT martinthierry idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT matuccicerinicmarco idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT moinzadehpia idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT montecuccocarlomaurizio idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT moraesfontesmariafrancisca idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT mouthonluc idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT nerirossella idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT paolinosabrina idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT pietteyves idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT rednicsimona idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT tamiroufarah idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT tincaniangela idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT toplaknatasa idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT bombardieristefano idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT hachullaeric idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT muellerladnerulf idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT schneidermatthias idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT smithvanessa idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT vieiraana idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT cutolomaurizio idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT moscamarta idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines AT cavagnalorenzo idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines |